


GROWTH OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS IN CHINA

An In-depth Study of Emerging Opportunities



HIGHLIGHTS

- Top Ranked CMO/CDMO Facilities in China
- Trends in the importance of Contract Manufacturing of biologics in China
- How CMOs are meeting the increased demand and rapid capacity expansions
- Analysis and Profile Directory of CMOs in China
- Much more...

NEW!

Comprehensive In-depth Study provides detailed analysis of the CMO industry, its recent development and trends. Profiles of China's Contract Manufacturing Organizations (CMOs) and Contract Development Manufacturing Organizations (CDMOs), including their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives.

TABLE OF CONTENTS

- Chapter 1:** Introduction: Brief History of China Biopharma Service Industry
- Chapter 2:** Legal Framework of MAH, Government Subsidy Program and Implications
- Chapter 3:** Innovation in China Biopharma and the Outsourcing of Commercial Scale Bioprocessing
- Chapter 4:** Using China-based Biologics CMOs
- Chapter 5:** China-based Biologics CMOs
- Chapter 6:** Domestic vs. Multinational Biologics CDMOs
- Appendix:** Featuring Biopharmaceutical CDMOs, Companies with Biologics and CMO Operations and Developer companies

Coverage 34 CMO/CDMOs including Industry Leaders:

- 3S Guojian
- Asymchem
- AutekBio
- Boehringer-Ingelheim
- Shanghai
- Canton Bio
- CC Pharming
- Celgen Pharma
- Celltrion
- Chempartner
- C-Mab
- Genescript
- HJB (Transcenta)
- Jiangsu T-Mab
- JOINN Biologics
- Lonza
- Mabplex, and more

TOPLINE FINDINGS

- China mAb Therapeutics expected to grow to USD \$26 billion by 2030, CMOs accessing an increasing share of domestic production
- Pipeline Growth in China is accelerating, as are markets for mAb therapeutics and vaccines
- Demand for biologics from domestic developers is increasing at 20% annually

BY THE NUMBERS:

- 35+ Chinese-owned Contract Manufacturing Organizations, plus up-and-coming facilities!
- 140+ pages
- Over 30+ Figures and 20 Tables

WHY THIS REPORT:

- This study will assist Western CMOs, and biopharma developers to make strategic decisions on why and when they should enter China market.
- Identify potential clients and partners in China for Western CMOs
- Analysis for Western mAb developers in partnering with China-based biologics CMO

CLICK HERE FOR MORE INFORMATION and TABLE OF CONTENTS



Top Ranked China CMO Facilities
ORDER YOUR COPY TODAY!

Order Global
e-License \$3450

Order Print
\$2450

Publisher: BioPlan Associates, Inc.
June 2020
ISBN: 978-1-934106-39-6